IRVINE, Calif., June 2, 2026 /PRNewswire/ -- Today Hyundai Motor Group Metaplant America (HMGMA) and Kia America (KUS) celebrated the start of production for...
CONSHOHOCKEN, Pa., June 2, 2026 /PRNewswire/ -- Quaker Houghton (NYSE: KWR), the global leader in industrial process fluids, today released its 2025 Sustainability Report,...
The limited-time in-game event invites players to take part in a global community effort supporting real coral reef restoration projects around the worldHERZLIYA, Israel,...
FARMINGTON, N.M., June 2, 2026 /PRNewswire/ -- Navajo Transitional Energy Company, LLC (NTEC) today announced the addition of nine new home solar installations under...
The initiative establishes a neutral interoperability standard to break down silos across the digital asset landscape and unify global enterprise infrastructureSAN FRANCISCO, June 2,...
While 70% of consumers trust nonprofit credit counseling, nearly half are unaware of the most effective solution for the $1.3 trillion national debt crisis:...
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...
TAIPEI, June 2, 2026 /PRNewswire/ -- Recharge Power (7921-TW), a pioneer and market leader in Taiwan's battery energy storage systems (BESS) industry, today announced...
Revenue Increased to $24.9 Million, Net Income Totaled $3.9 Million, and Cash & Marketable Securities Increased to Approximately $31 Million VANCOUVER, BC, June 1, 2026...
Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.